Novo Nordisk

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – BGI and Novo Nordisk today announced a collaboration to create a "global collaboration framework."

The Danish drug developer will use TET Systems' gene expression tools at its research institute.

The Novo Nordisk-funded center will use proteomics and other approaches for disease studies.

The diabetes care company will use the software under a multi-year agreement.

Seahorse acquired the maker of the SimCell System, a fully integrated cell culture automation system used for selecting clones, optimizing media, and determining the best process conditions for protein manufacturing, for an undisclosed sum. It also raised $6 million in funding from VC investors.